Influence of demand-side measures to enhance renin–angiotensin prescribing efficiency in Europe: implications for the future

References

• Godman B, Buscics A, Burkhardt T et al. Initiatives to enhance renin-angiotensin prescribing efficiency in Austria; impact and implications for other countries. Expert Rev. Pharmacoeconomics Outcomes Res.10, 199–207 (2010).
   PubMed Web of Science ®Google Scholar
• Frisk P, Mellgren T-O, Hedberg N et al. Utilisation of angiotensin blockers in Sweden combining survey and register data to study adherence to prescribing guidelines. Eur. J. Clin. Pharmacol.64, 1223–1229 (2008).
   PubMed Web of Science ®Google Scholar
• Fletcher A, Palmer A, Bulpitt C. Coughing with angiotensin converting enzyme inhibitors; how much of a problem? J. Hypertens.12, S43–S47 (1994).
   Google Scholar
• Elliot H. Focus on the ONTARGET results. J. Hypertens.27, S8–S10 (2009).
   Google Scholar
• McDowell S, Coleman J, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine Br. Med. J.332, 1177–1181 (2006).
   PubMed Web of Science ®Google Scholar
• Cramer JA, Benedict A, Muszabek N et al. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int. J. Clin. Pract.62, 76–87 (2008).
   PubMed Web of Science ®Google Scholar
• Coma A, Zara C, Godman B, Augusti A et al. Policies to enhance the efficiency of prescribing in the Spanish Catalan Region: impact and future direction. Expert Rev. Pharmacoeconomics Outcomes Res.9, 569–581 (2009).
   PubMedGoogle Scholar
• Godman B, Wettermark B, Hoffman M et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev. Pharmacoeconomcis Outcomes Res.9, 65–83 (2009).
   PubMedGoogle Scholar
• Wettermark B, Pehrsson A, Juhasz-Haverinen M et al. Financial incentives linked to self-assessment of prescribing patterns – a new approach for quality improvement of drug prescribing in primary care. Qual. Primary Care17, 179–189 (2009).
   PubMedGoogle Scholar
• Gustafsson LL, Wettermark B, Godman B et al. The ‘Wise List’ – a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin. Pharmacol. Toxicol.108, 224–233 (2011).
   PubMed Web of Science ®Google Scholar
• Wettermark B, Godman B, Neovius M et al. Initial effects of a reimbursement restriction to improve the cost–effectiveness of antihypertensive treatment. Health Policy94, 221–229 (2010).
   PubMed Web of Science ®Google Scholar
• Johnston A, Stafylas P, Stergiou G. Effectiveness, safety and cost of drug substitution in hypertension. Br. J. Clin. Pharmacol.70, 320–334 (2010).
   PubMed Web of Science ®Google Scholar
• Norman C, Zarrinkoub R, Hasselström J et al. Potential savings without compromising the quality of care. Int. J. Clin. Pract.63, 1320–1326 (2009).
   PubMed Web of Science ®Google Scholar
• Usher-Smith J, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int. J. Clin. Pract.62, 480–484 (2008).
   PubMed Web of Science ®Google Scholar
• Godman B, Shrank W, Wettermark B et al. Use of generics – a critical cost containment measure for all healthcare professionals in Europe? Pharmaceuticals3, 2470–2494 (2010).
   Google Scholar
• Godman B, Shrank W, Andersen M et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilisation: changes seen and global implications. Expert Rev. Pharmacoeconomics Outcomes Res.10, 707–722 (2010).
   PubMed Web of Science ®Google Scholar
• Godman B, Shrank W, Andersen M et al. Policies to enhance prescribing efficiency in Europe: findings and future implications. Front. Pharmacol.1(141), 1–16 (2011).
   Google Scholar
• Moon J, Flett A, Godman B et al. Getting better value from the NHS drug budget. Br. Med. J.342, 30–32 (2011).
   Google Scholar
• Staessen JA, Li Y, Thijs L, Wang JG. Blood pressure reduction and cardiovascular prevention: an update including the 2003–2004 secondary prevention trials. Hypertens. Res.28, 385–407 (2005).
   PubMed Web of Science ®Google Scholar
• Mancia G, Laurent S, Agabiti-R et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens.27, 2121–2158 (2009).
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension42, 1206–1252 (2003)
   PubMed Web of Science ®Google Scholar
• Rønning M, Blix HS, Harbø BT, Strøm H. Different versions of the anatomical therapeutic chemical classification system and the defined daily dose – are drug utilisation data comparable? Eur. J. Clin. Pharmacol.56, 723–727 (2000).
   PubMed Web of Science ®Google Scholar
• Vlahovic-Palcevski V, Gantumur M, Radosevic N et al. Coping with changes in defined daily dose in longitudinal drug consumption databases. Pharm. World Sci.32, 125–129 (2010).
   PubMedGoogle Scholar
• Wettermark B, Vlahovic-Palcevski V, Salvesen H et al. Drug Utilisation Research. In: Pharmacoepidemiology and Therapeutic Risk Management. Hartzema A, Tilson H, Chan K (Eds). Harvey Whitney Books Company, OH, USA (2008).
   Google Scholar
• Wettermark B, Godman B, Jacobsson B, Haaijer-Ruskamp F. Soft regulations in pharmaceutical policymaking – an overview of current approaches and their consequences. Appl. Health Econ. Health Policy7(3), 137–147 (2009).
   PubMedGoogle Scholar
• McGinn D, Godman B, Lonsdale J et al. Initiatives to enhance the efficiency of statin and proton pump inhibitor prescribing in the UK: impact and implications. Expert Rev. Pharmacoeconomics Outcomes Res.10, 73–85 (2010).
   PubMed Web of Science ®Google Scholar
• Godman B, Sakshaug S, Berg C, Wettermark B, Haycox A. Combination of prescribing restrictions and aggressive generic pricing policies – an alternative approach to conserve resources? Expert Rev. Pharmacoeconomics Outcomes Res.11, 121–129 (2011).
   PubMed Web of Science ®Google Scholar
• Godman B, Burkhardt T, Bucsics A et al. Impact of recent reforms in Austria on utilisation and expenditure of PPIs and lipid lowering drugs: implications for the future. Expert Rev. Pharmacoeconomics Outcomes Res.9, 475–484 (2009).
   PubMedGoogle Scholar
• Barton S. Using clinical evidence. Br. Med. J.322, 503–504 (2001).
   PubMed Web of Science ®Google Scholar
• Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patient’s care. Lancet362, 1225–1230 (2003).
   PubMed Web of Science ®Google Scholar
• Bero LA, Grilli R, Grimshaw JM et al. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. Br. Med. J.317, 465–468 (1998).
   PubMed Web of Science ®Google Scholar
• Doran T, Fullwood C, Gravelle H et al. Pay-for-performance programs in family practices in the United Kingdom. N. Engl. J. Med.355, 375–384 (2006).
   PubMed Web of Science ®Google Scholar
• Collins R, Armitage J, Parish S et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 with diabetes: a randomised placebo-controlled trial. Lancet361, 2005–2016 (2003).
   PubMed Web of Science ®Google Scholar
• Roland M. Linking physicians’ pay to the quality of care – a major experiment in the United Kingdom. N. Engl. J. Med.351, 1448–1454 (2004).
   PubMed Web of Science ®Google Scholar
• Voncina L, Strizrep T. Croatia: 2009/2010 pharmaceutical pricing and reimbursement forum. Eurohealth16, 20–22 (2010).
   Google Scholar
• Bangalore S, Kamalakkannan G, Parkar S, Messerli F. Fixed-dose combinations improve medication compliance: a meta analysis. Am. J. Med.120, 713–719 (2007).
   PubMed Web of Science ®Google Scholar